The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance

Cancer Research

Volumn 66, Issue 11, 2006, Pages 5781-5789

  Maiso, Patricia ^a   Carvajal Vergara, Xonia ^a   Ocio, Enrique M ^a,b   López Pérez, Ricardo ^a   Mateo, Gema ^b   Gutiérrez, Norma ^a,b   Atadja, Peter ^c   Pandiella, Atanasio ^a,d   San Miguel, Jesus F ^a,b  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^c NOVARTIS PHARMA AG   (Switzerland)

^d Centro de Investigacion del Cancer   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; APOPTOSOME; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; ARSENIC TRIOXIDE; BORTEZOMIB; CASPASE 9; CYTOCHROME C; DEXAMETHASONE; DOXORUBICIN; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; LBH 589; LENALIDOMIDE; MELPHALAN; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN P21; PROTEIN P53; PROTEIN P57; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; DNA MICROARRAY; DOWN REGULATION; DRUG DNA INTERACTION; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME RELEASE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IC 50; MEMBRANE PERMEABILITY; MITOCHONDRIAL MEMBRANE; MULTIPLE MYELOMA; MYELOMA CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DEGRADATION; UPREGULATION; WESTERN BLOTTING;

ACETYLATION; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BCL-X PROTEIN; BORONIC ACIDS; CELL CYCLE; CELL LINE, TUMOR; DEXAMETHASONE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MELPHALAN; MULTIPLE MYELOMA; PYRAZINES;

EID: 33745258655     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-4186     Document Type: Article

References (34)

1. Miller TA, Witter DJ, Belvedere S. Histone deacetylase inhibitors. J Med Chem 2003;46:5097-116.
2. Drummond DC, Noble CO, Kirpotin DB, Quo Z, Scott GK, Benz CC. Clinical development of histone deacetylase inhibitors us anticancer agents. Annu Rev Pharmacol Toxicol 2005;45:495-528.
3. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001;1:194-202.
4. Yang XJ, Gregoire S. Class II histone deacetylases: from sequence to function, regulation, and clinical implication. Mol Cell Biol 2005;25:2873-84.
5. Peart MJ, Tainton KM, Ruefli AA, et al. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res 2003;63:4460-71.
6. Mitsiades N, Mitsiades CS, Richardson PG, et al. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 2003;101:4055-62.
7. Shao Y, Gao Z, Marks PA, Jiang X. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci U S A 2004;101:18030-5.
8. Ruefli AA, Ausserlechner MJ, Bernhard D, et al. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci U S A 2001;98:10833-8.
9. Henderson C, Mizzau M, Paroni G, Maestro R, Schneider C, Brancolini C. Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA). J Biol Chem 2003;278:12579-89.
10. Amin HM, Saeed S, Alkan S. Histone deacetylase inhibitors induce caspase-dependent apoptosis and downregulation of daxx in acute promyelocytic leukaemia with t(15;17). Br J Haematol 2001;115:287-97.
11. Khan SB, Maududi T, Barton K, Ayers J, Alkan S. Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma. Br J Haematol 2004;125:156-61.
12. Anderson KC. Moving disease biology from the lab to the clinic. Cancer 2003;97:796-801.
13. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A 2004;101:540-5.
14. Catley L, Weisberg E, Tai YT, et al. NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood 2003;102:2615-22.
15. George P, Bali P, Annavarapu S, et al. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 2005;105:1768-76.
16. Chau BN, Cheng EH, Kerr DA, Hardwick JM. Aven, a novel inhibitor of caspase activation, binds Bcl-xL and Apaf-1. Mol Cell 2000;6:31-40.
17. Hitoshi Y, Lorens J, Kitada SI, et al. Toso, a cell surface, specific regulator of Fas-induced apoptosis in T cells. Immunity 1998;8:461-71.
18. Song Y, Jacob CO. The mouse cell surface protein TOSO regulates Fas/Fas ligand-induced apoptosis through its binding to Fas-associated death domain. J Biol Chem 2005;280:9618-26.
19. Shiiki K, Yoshikawa H, Kinoshita H, et al. Potential mechanisms of resistance to TRAIL/Apo2L-induced apoptosis in human promyelocytic leukemia HL-60 cells during granulocytic differentiation. Cell Death Differ 2000;7:939-46.
20. Carvajal-Vergara X, Tabera S, Montera JC, et al. Multifunctional role of Erk5 in multiple myeloma. Blood 2005;105:4492-9.
21. Orfao A, Garcia-Sanz R, Lopez-Berges MC, et al. A new method for the analysis of plasma cell DNA content in multiple myeloma samples using a CD38/propidium iodide double staining technique. Cytometry 1994;17:332-9.
22. Gajate C, Santos-Beneit AM, Macho A, et al. Involvement of mitochondria and caspase-3 in ET-18-OCH(3)-induced apoptosis of human leukemic cells. Int J Cancer 2000;86:208-18.
23. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334-6.
24. Mitsiades CS, Mitsiades N, Munshi NC, Anderson KC. Focus on multiple myeloma. Cancer Cell 2004;6:439-44.
25. Malumbres M, Hunt SL, Sotillo R, et al. Driving the cell cycle to cancer. Adv Exp Med Biol 2003;532:1-11.
26. Cartel AL, Tyner AL. Transcriptional regulation of the p21((WAF1/CIP1)) gene. Exp Cell Res 1999;246:280-9.
27. Ogata A, Chauhan D, Teoh G, et al. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J Immunol 1997;159:2212-21.
28. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61:3071-6.
29. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 2004;116:205-19.
30. Kroemer G, Martin SJ. Caspase-independent cell death. Nat Med 2005;11:725-30.
31. Hideshima T, Chauhan D, Hayashi T, et al. Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene 2003;22:8386-93.
32. Mitsiades N, Mitsiades CS, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A 2002;99:14374-9.
33. 1-phase progression. Genes Dev 1999;13:1501-12.
34. Peart MJ, Smyth GK, van Laar RK, et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci U S A 2005;102:3697-702.